Skye Bioscience Advances Nimacimab Development with Phase 2b Planning
Event summary
- Skye Bioscience initiated Cohort 1 of the CBeyond Expansion Study for nimacimab, with a Cohort Review Committee review scheduled for May 18, 2026.
- The company engaged Lilly Catalyze360 for strategic guidance on nimacimab's target product profile and Phase 2b trial design.
- Skye reported $17.1 million in cash and short-term investments as of March 31, 2026, expecting it to fund operations through Q4 2026.
- Q1 2026 R&D expenses increased to $7.9 million from $7.2 million in Q1 2025, driven by clinical trial and manufacturing costs.
The big picture
Skye Bioscience is positioning nimacimab as a complementary therapy to GLP-1 agonists for obesity treatment, a growing market with significant unmet needs. The company's strategic engagements with Lilly Catalyze360 and Halozyme underscore its focus on optimizing the drug's development path and delivery mechanism. Success in the CBeyond Expansion Study could pave the way for a pivotal Phase 2b trial, but financial constraints remain a key challenge.
What we're watching
- Clinical Progress
- Whether the Cohort Review Committee approves the initiation of Cohort 2 in the CBeyond Expansion Study, which is critical for advancing nimacimab's development.
- Regulatory Strategy
- How Skye incorporates FDA feedback into its Phase 2b trial design, particularly around dose selection and patient population.
- Financial Sustainability
- The pace at which Skye depletes its cash reserves and whether it needs to raise additional capital to fund the anticipated Phase 2b study.
Related topics